Ocumetics Lens First-in-Human Patients Reach 12-Month Clinical Follow-Up Milestone

Calgary, Alberta — September 17, 2026 — Leads & Copy — Ocumetics Technology Corp. is announcing that patients in its first-in-human Group One clinical study for its accommodating intraocular lens, known as the Ocumetics Lens, have reached their 12-month follow-up milestone. This development marks a significant point in the company's clinical program for the lens, designed to offer a more natural range of vision and address limitations of conventional intraocular lenses.

The company indicated that visual outcomes for patients in the Group One study continued to improve through the one, three, and six-month follow-up visits. These results are supporting the further advancement of the Ocumetics Lens program. Patients have reported an enhanced ability to perform everyday activities, including reading, watching television, and recognizing family members. Notably, one patient who was previously legally blind achieved vision that now qualifies them to drive.

The Group One study provided encouraging clinical evidence that the company stated is needed for future development and regulatory milestones. Ocumetics is preparing to move to the next phase of patient recruitment. Unlike Group One, which primarily focused on safety, the primary and secondary objectives of the upcoming Group Two surgeries will investigate the safety, distance vision, and near vision performance of the Ocumetics Lens.

Dean Burns, President and CEO of Ocumetics Technology Corp., emphasized the significance of each clinical milestone, stating that some matter for reasons beyond quantitative data. He noted that at one month, evidence of meaningful functional vision was observed. By three months, these early results were developing, and important internal clinical benchmarks were being met. At six months, patients began to describe how their improved vision was impacting their daily lives.

At approximately one month post-surgery, all patients achieved 20/40 or better distance vision. For those who started the study with significant visual impairment, this represented a substantial improvement in functional vision and indicated the Ocumetics Lens could be safely implanted and potentially deliver meaningful visual benefits.

By the three-month mark, Group One patient results met or exceeded the Company's internal benchmarks for safety, lens delivery, and foundational distance vision performance, supporting the decision to advance the clinical development program.

At six months post-surgery, patients continued to show encouraging visual outcomes, with a consistent safety profile. Patients began articulating the positive impact of improved vision on their everyday lives, including greater visual independence in activities such as reading, watching television, and recognizing loved ones. In one instance, a previously legally blind patient attained vision sufficient to qualify for a driver's license.

Ocumetics highlighted that these experiences underscore the potential impact of its lens technology beyond standard eye chart measurements. The company is now commencing 12-month follow-up examinations for Group One patients. Longer-term follow-up is considered crucial for gathering additional information on the durability of visual outcomes and the ongoing safety and performance of the Ocumetics Lens. Ocumetics intends to release relevant clinical information as it becomes available.

The company stressed that these are early, first-in-human results and should not be interpreted as definitive proof of safety or efficacy. Further patients, additional clinical data, longer-term follow-up, and further clinical and regulatory evaluation will be necessary as the program progresses. Burns reiterated that the company's objective is to develop a technology offering a more natural range of vision and greater visual freedom without side effects. He expressed confidence that the journey from one month to twelve months has provided the team, clinical investigators, and shareholders with increasing reasons to believe in the technology's potential.

Ocumetics Technology Corp. is a Canadian research and product development company focused on creating advanced vision correction solutions. The company's technology involves a dynamic intraocular lens designed to fit within the eye's natural lens compartment, potentially eliminating the need for corrective lenses. It is engineered to use the eye's natural muscle activity to shift focus between distance and near, providing clear vision at all distances without glasses or contact lenses and without perceptible time lag.

Source: Ocumetics Technology Corp.